IP Library Granted Patent US 8,765,734
Granted Patent B2
US 8,765,734 · App. 13/043,986 · Granted Jul 1, 2014

Piperidin-4-yl azetidine derivatives as JAK1 inhibitors

Inventors: Taisheng Huang (Wilmington, DE); Chu-Biao Xue (Hockessin, DE); Hui-Yin Li (Hockessin, DE); Qun Li (Newark, DE)
Assignee: Incyte Corporation
C07D401/14C07D471/04C07D405/14C07D487/04C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,765,734
App. No.
13/043,986
Granted
Jul 1, 2014
Kind
B2
Abstract

The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Claims (12)

1. A compound, which is {1-{1-[3-Fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

2. A salt, which is {1-{1-[3-Fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipic acid salt.

3. A composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4. A composition comprising a salt according to claim 2 and a pharmaceutically acceptable carrier.

5. A compound, which is {1-{1-[3-Fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile.

6. A composition comprising a compound according to claim 5 and a pharmaceutically acceptable carrier.

7. The salt according to claim 2 , which is characterized by a melting point of about 178° C.

8. The salt according to claim 2 , having a differential scanning calorimetry thermogram which is characterized by an endothermic peak with an onset temperature of about 176° C.

9. The salt according to claim 2 , having a differential scanning calorimetry thermogram substantially as shown in FIG. 1 .

10. The salt according to claim 2 , having a thermal gravimetric analysis thermogram substantially as shown in FIG. 2 .

11. The salt according to claim 2 , having an X-ray powder diffraction pattern comprising characteristic peaks expressed in degrees 2θ at about 6.9, 10.4, 21.0, and 23.3.

12. The salt according to claim 2 , having an X-ray powder diffraction pattern substantially as shown in FIG. 3 .

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE OMMISSION OF SECOND RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 035292 FRAME: 0004. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 2, 2015
From: INCYTE CORPORATION
To: INCYTE HOLDINGS CORPORATION; INCYTE CORPORATION
Reel/Frame 036054/0696 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2015
From: INCYTE CORPORATION
To: INCYTE HOLDINGS CORPORATION AND INCYTE CORPORATION
Reel/Frame 035924/0004 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2011
From: HUANG, TAISHENG; XUE, CHU-BIAO; WANG, ANLAI; KONG, LING QUAN; YE, HAI FEN; YAO, WENQING; RODGERS, JAMES D.; SHEPARD, STACEY; WANG, HAISHENG; SHAO, LIXIN; LI, HUI-YIN; LI, QUN
To: INCYTE CORPORATION
Reel/Frame 026467/0672 →
Continuity (3)
Provisional Application 61312588 · Mar 10, 2010
Provisional Application 61415602 · Nov 19, 2010
Related Publication 20110224190A1 · Sep 15, 2011